EAM
AXSM icon

Eagle Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Eagle Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$7.46M Sell
82,791
-15,854
-16% -$1.38M 0.04% 348
2024
Q2 		$7.99M Sell
98,645
-127,870
-56% -$9.47M 0.04% 323
2024
Q1 		$17.4M Buy
+226,515
New +$19M 0.09% 207

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Asset Management's AXSM Position: Q3 2024 in Review

Eagle Asset Management reduced its Axsome Therapeutics (AXSM) stake by 16% in Q3 2024, selling an estimated $1.38M and leaving 82,791 shares worth $7.46M. The position accounts for 0.04% of the portfolio, ranked #348.

Eagle Asset Management first reported a position in AXSM in Q1 2024 and has held it in 3 quarters since. The position peaked at $17.4M in Q1 2024. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Eagle Asset Management held 82,791 shares of Axsome Therapeutics worth $7.46M as of Q3 2024.
  • Eagle Asset Management sold 15,854 Axsome Therapeutics shares in Q3 2024, an estimated $1.38M.
  • Axsome Therapeutics made up 0.04% of Eagle Asset Management's portfolio in Q3 2024, its #348 holding.
  • Eagle Asset Management first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Eagle Asset Management's Axsome Therapeutics position peaked at $17.4M in Q1 2024.
  • 279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.